Lexeo Therapeutics appointed Dr. Kyle Rasbach as Chief Financial Officer, effective December 18, 2024, with a base salary of $480,000 and potential bonuses and stock options. His previous roles include Chief Business Officer at Zentalis Pharmaceuticals and managing positions at Eventide Asset Management and Pappas Capital.